Low-density lipoprotein reduction: Is the risk worth the benefit?

Current Atherosclerosis Reports

Volumn 8, Issue 1, 2006, Pages 19-25

  Sabharwal, Anup K ^b   Boord, Jeffrey B ^a  

^a Education and Clinical Center   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ANTIFUNGAL AGENT; ANTILIPEMIC AGENT; ATORVASTATIN; BILE ACID; CERIVASTATIN; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; CREATINE KINASE; DILTIAZEM; EZETIMIBE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MACROLIDE; MEVINOLIN; NICOTINIC ACID; PLACEBO; PRAVASTATIN; SIMVASTATIN; TIROFIBAN; TORCETRAPIB; TRIACYLGLYCEROL; VERAPAMIL;

CLINICAL STUDY; CLINICAL TRIAL; DATA ANALYSIS; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DRUG TARGETING; DYSLIPIDEMIA; EPIDEMIOLOGICAL DATA; HIGH RISK PATIENT; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; LIVER FUNCTION TEST; LIVER TOXICITY; LOW DRUG DOSE; MYOPATHY; OUTCOME ASSESSMENT; PERIPHERAL NEUROPATHY; PRACTICE GUIDELINE; REVIEW; RHABDOMYOLYSIS; RISK ASSESSMENT; RISK BENEFIT ANALYSIS;

CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; CLINICAL TRIALS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; RISK;

EID: 33646425829     PISSN: 15233804     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11883-006-0060-6     Document Type: Review

References (32)

1. Grundy SM, Cleeman JI, Merz CN, et al.: Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004, 110:227-239.
2. Waters DD, Guyton JR, Herrington DM, et al.: Treating to New Targets (TNT) Study: does lowering low-density lipoprotein cholesterol levels below currently recommended guidelines yield incremental clinical benefit? Am J Cardiol 2004, 93:154-158.
3. O'Keefe JH Jr, Cordain L, Harris WH, et al.: Optimal low-density lipoprotein is 50 to 70 mg/dl: lower is better and physiologically normal. J Am Coll Cardiol 2004, 43:2142-2146.
4. Shepherd J, Blauw GJ, Murphy MB, et al.: Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002, 360:1623-1630.
5. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA 2002, 288:2998-3007.
6. Pasternak RC: The ALLHAT lipid lowering trial - less is less. JAMA 2002, 288:3042-3044.
7. Sever PS, Dahlof B, Poulter NR, et al.: Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003, 361:1149-1158.
8. Colhoun HM, Betteridge DJ, Durrington PN, et al.: Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004, 364:685-696.
9. Wanner C, Krane V, Marz W, et al.: Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005, 353:238-248.
10. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002, 360:7-22.
11. Nissen SE, Tuzcu EM, Schoenhagen P, et al.: Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 2004, 291:1071-1080.
12. Schwartz GG, Olsson AG, Ezekowitz MD, et al.: Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 2001, 285:1711-1718.
13. Cannon CP, Braunwald E, McCabe CH, et al.: Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004, 350:1495-1504.
14. de Lemos JA, Blazing MA, Wiviott SD, et al.: Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA 2004, 292:1307-1316.
15. Pasternak RC, Smith SC Jr, Bairey-Merz CN, et al.: ACC/AHA/NHLBI clinical advisory on the use and safety of statins. Circulation 2002, 106:1024-1028.
16. Thompson PD, Clarkson P, Karas RH: Statin-associated myopathy. JAMA 2003, 289:1681-1690.
17. Sacher J, Weigl L, Werner M, et al.: Delineation of myotoxicity induced by HMG-CoA-reductase-inhibitors in human skeletal muscle cells. J Pharmacol Exp Ther 2005, In press.
18. Bellosta S, Paoletti R, Corsini A: Safety of statins: focus on clinical pharmacokinetics and drug interactions. Circulation 2004, 109(23 Suppl 1): III50-III57.
19. Weverling-Rijnsburger AW, Blauw GJ, Lagaay AM, et al.: Total cholesterol and risk of mortality in the oldest old. Lancet 1997, 350:1119-1123.
20. Fassbender K, Simons M, Bergmann C, et al.: Simvastatin strongly reduces levels of Alzheimer's disease beta-amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo. Proc Natl Acad Sci U S A 2001, 98:5856-5861.
21. Dufouil C, Richard F, Fievet N, et al.: APOE genotype, cholesterol level, lipid-lowering treatment, and dementia: the Three-City Study. Neurology 2005, 64:1531-1538.
22. Jick H, Zornberg GL, Jick SS, et al.: Statins and the risk of dementia. Lancet 2000, 356:1627-1631.
23. Rea TD, Breitner JC, Psaty BM, et al.: Statin use and the risk of incident dementia: the Cardiovascular Health Study. Arch Neurol 2005, 62:1047-1051.
24. Backes JM, Howard PA: Association of HMG-CoA reductase inhibitors with neuropathy. Ann Pharmacother 2003, 37:274-278.
25. Gaist D, Garcia Rodriguez LA, Huerta C, et al.: Are users of lipid-lowering drugs at increased risk of peripheral neuropathy? Eur J Clin Pharmacol 2001, 56:931-933.
26. Gaist D, Jeppesen U, Andersen M, et al.: Statins and risk of polyneuropathy: a case-control study. Neurology 2002, 58:1333-1337.
27. Rubins HB, Robins SJ, Collins D, et al.: Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999, 341:410-418.
28. Robins SJ, Collins D, Wittes JT, et al.: Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. JAMA 2001, 285:1585-1591.
29. LaRosa JC, Gotto AM Jr: Past, present, and future standards for management of dyslipidemia. Am J Med 2004, 116(Suppl 6A):3S-8S.
30. Brown BG, Zhao XQ, Chait A, et al.: Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001, 345:1583-1592.
31. Brousseau ME, Schaefer EJ, Wolfe ML, et al.: Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl J Med 2004, 350:1505-1515.
32. Ong HT: The statin studies: from targeting hypercholesterolaemia to targeting the high-risk patient. Quart J Med 2005, 98:599-614.